ATE408840T1 - Verfahren zur identifizierung von agenzien zur behandlung von anfällen, neurologischen erkrankungen, endokrinopathien und hormonalen erkrankungen - Google Patents
Verfahren zur identifizierung von agenzien zur behandlung von anfällen, neurologischen erkrankungen, endokrinopathien und hormonalen erkrankungenInfo
- Publication number
- ATE408840T1 ATE408840T1 AT03027613T AT03027613T ATE408840T1 AT E408840 T1 ATE408840 T1 AT E408840T1 AT 03027613 T AT03027613 T AT 03027613T AT 03027613 T AT03027613 T AT 03027613T AT E408840 T1 ATE408840 T1 AT E408840T1
- Authority
- AT
- Austria
- Prior art keywords
- diseases
- endocrinopathies
- identifying agents
- hormonal
- treating seizures
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 230000003054 hormonal effect Effects 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 101000584505 Homo sapiens Synaptic vesicle glycoprotein 2A Proteins 0.000 abstract 4
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000012512 characterization method Methods 0.000 abstract 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 abstract 1
- 229960004002 levetiracetam Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/308,163 US7090985B2 (en) | 2002-12-03 | 2002-12-03 | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE408840T1 true ATE408840T1 (de) | 2008-10-15 |
Family
ID=32312217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03027613T ATE408840T1 (de) | 2002-12-03 | 2003-12-02 | Verfahren zur identifizierung von agenzien zur behandlung von anfällen, neurologischen erkrankungen, endokrinopathien und hormonalen erkrankungen |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7090985B2 (de) |
| EP (1) | EP1426768B1 (de) |
| AT (1) | ATE408840T1 (de) |
| DE (1) | DE60323592D1 (de) |
| ES (1) | ES2311667T3 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004051222A2 (en) * | 2002-12-03 | 2004-06-17 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| DK1718756T3 (da) * | 2004-02-24 | 2012-02-27 | Allergan Inc | Botulinumtoksinscreeningassays |
| WO2006090275A1 (en) * | 2005-02-24 | 2006-08-31 | Pfizer Limited | Treatment of incontinence |
| DE102005046526A1 (de) * | 2005-09-28 | 2007-04-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Variante des humanen SV2A-Proteins und deren Einfluss auf die Therapieantwort bei Epilepsie |
| US7985554B2 (en) | 2005-10-14 | 2011-07-26 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin A receptor and the use thereof |
| US20090042835A1 (en) * | 2006-06-02 | 2009-02-12 | Davis Roger A | Compositions and methods for ameliorating hyperlipidemia |
| EP2037929A4 (de) * | 2006-06-02 | 2010-02-17 | Univ San Diego State Res Found | Zusammensetzungen und verfahren zur linderung von hyperlipidämie |
| US8735356B2 (en) | 2006-06-15 | 2014-05-27 | Ucb Pharma Gmbh | Anticonvulsant combination therapy |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| US20110212944A1 (en) * | 2008-07-01 | 2011-09-01 | Julie Liu | 2-oxo-1-pyrrolidine derivatives |
| EP3260118B1 (de) | 2008-10-16 | 2021-03-24 | The Johns Hopkins University | Verfahren und zusammensetzungen zur verbesserung der kognitiven funktion |
| US20110212928A1 (en) * | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2012109491A1 (en) * | 2011-02-09 | 2012-08-16 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2492354A1 (de) * | 2011-02-23 | 2012-08-29 | Institut National De La Recherche Agronomique (INRA) | Verfahren zur Identifizierung von Verbindungen zur Behandlung lichtempfindlicher Reflexepilepsie |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| CN119569868A (zh) * | 2023-09-05 | 2025-03-07 | 兰州大学 | 一种sv2受体胞外域纳米抗体及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142383A1 (en) | 2001-04-02 | 2002-10-03 | Merkulov Gennady V. | Isolated nucleic acid molecules encoding human transport proteins |
| EP1266906A1 (de) | 2001-06-13 | 2002-12-18 | Millennium Pharmaceuticals, Inc. | 46584, ein Mitglied aus der Familie menschlicher Transportproteine und seine Anwendungen |
| WO2004051222A2 (en) * | 2002-12-03 | 2004-06-17 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
-
2002
- 2002-12-03 US US10/308,163 patent/US7090985B2/en not_active Expired - Fee Related
-
2003
- 2003-12-02 AT AT03027613T patent/ATE408840T1/de not_active IP Right Cessation
- 2003-12-02 ES ES03027613T patent/ES2311667T3/es not_active Expired - Lifetime
- 2003-12-02 EP EP03027613A patent/EP1426768B1/de not_active Expired - Lifetime
- 2003-12-02 DE DE60323592T patent/DE60323592D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1426768A3 (de) | 2006-08-30 |
| US20040106147A1 (en) | 2004-06-03 |
| DE60323592D1 (de) | 2008-10-30 |
| US7090985B2 (en) | 2006-08-15 |
| ES2311667T3 (es) | 2009-02-16 |
| EP1426768B1 (de) | 2008-09-17 |
| EP1426768A2 (de) | 2004-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60323592D1 (de) | Verfahren zur Identifizierung von Agenzien zur Behandlung von Anfällen, neurologischen Erkrankungen, Endokrinopathien und hormonalen Erkrankungen | |
| WO2004051222A3 (en) | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases | |
| ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| DE69939058D1 (de) | Vorrichtung zur behandlung von peripheren gefässerkrankungen | |
| ATE435012T1 (de) | Verfahren zur behandlung von parkinson-krankheit | |
| DE60027551D1 (de) | Zusammensetzungen und verfahren zur regulierung des serumcholesterins | |
| DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
| DE69829336D1 (de) | Vorrichtung und Verfahren zur Behandlung von Körpergewebe | |
| DE69807538D1 (de) | Vorrichtung und Verfahren zur Behandlung von Gewebe | |
| EP1701664A4 (de) | System und verfahren zur behandlung von gewebe | |
| ATE490964T1 (de) | Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen | |
| ATE230617T1 (de) | Verfahren und methode zur behandlung von abfällen | |
| DE602004010267D1 (de) | Zusammensetzung mit mindestens einem substituiertem 2- 2-(4-aminophenyl)ethenyl -1-pyridinium-derivat, verfahren zur behandlung von keratinfasern damit, vorrichtung und verwendung | |
| EP0820467A4 (de) | Verfahren zur behandlung von augenkrankheiten | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| EP1109548A4 (de) | Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole | |
| ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| ATE368110T1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| EP1542702A4 (de) | Verfahren und zusammensetzungen zur behandlung von neurologischen störungen | |
| DE50213931D1 (de) | Verfahren und vorrichtung zur behandlung von fehlerverdacht | |
| DE69906384D1 (de) | Verfahren und vorrichtung zur direktreduktion von eisenerzen | |
| ATE371453T1 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
| ATE470453T1 (de) | Verfahren zur behandlung von atherosklerose | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| DE602004010548D1 (de) | Verfahren zur behandlung von tierhäuten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties | ||
| REN | Ceased due to non-payment of the annual fee |